Quick medicine delivery startup Plazza has raised $15 million in a Series A round co-led by Accel, Elevation Capital, and Nexus Venture Partners. Existing investors All In Capital and Better Capital also participated. The company did not disclose its valuation.
Founded in 2024, Plazza operates an omnichannel pharmacy model with physical stores that double as hyperlocal distribution hubs. The company stocks over 40,000 SKUs per store — roughly eight times the inventory of a typical retail pharmacy — and fulfills orders in 15 to 30 minutes through its app and WhatsApp.
An AI-driven inventory system tailors each store’s assortment to neighbourhood-level prescribing patterns. Across its two existing Bengaluru locations, only about 50% of the top-selling medicines overlap, a data point the company cites as evidence of how sharply micro-market demand varies.
Why it matters
India’s organised pharmacy market is consolidating around large players like Tata 1mg and Apollo 24/7, but the segment still leaves gaps. Plazza’s bet is that speed and inventory breadth — delivered from a physical footprint optimised by AI — can pull demand away from both walk-in chemists (which carry limited stock) and online platforms (which optimise for catalog size over delivery time).
For a global partner or investor, the thesis is simple: neighbourhood-level demand intelligence applied to an essential, high-frequency category. The company reports its GMV grew roughly 27x between June 2025 and March 2026 on a small base, and it plans to reach over 3,000 stores in the next three to four years.
Aman Priyadarshi, founder and CEO, told Mint: "We have a couple of stores in Bengaluru that we have been experimenting with, and now we've raised capital to increase our geographical footprint. We are launching about 10 stores very quickly in the next eight weeks, and we will have about 20 stores in the city by the end of this year." The company expects to expand to other cities within a year.
